Related Experiment Video
Updated: May 13, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma
Feifei Chen1, Jin Bai, Wang Li
1Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, China.
Abstract:
RUNX3 (runt-related transcription factor-3) is a known tumor suppressor gene which exhibits potent antitumor activity in several carcinomas. However, little is known about the role of RUNX3 in human renal cell carcinoma (RCC). To investigate the clinical relevance of RUNX3 in RCC patients, immunohistochemistry was performed to detect the clinical relevance of RUNX3 in 75 RCC tissues and paired non-cancerous tissues by using tissue microarray (TMA). We also investigated the role of RUNX3 in RCC cell migration, invasion and angiogenesis. The RUNX3 expression was decreased dramatically in human RCC tissue. The RUNX3 expression was significantly correlated with tumor size (P<0.001), depth of invasion (P<0.001), and of TNM stage (P<0.001). Restoration of RUNX3 significantly decreased renal carcinoma cell migration and invasion capacity compared with controls. In addition, we found that overexpression of RUNX3 reduced the proliferation and tube formation of human umbilical vascular endothelial cells (HUVECs). Gelatin zymography and Western blot showed that RUNX3 expression suppressed matrix metalloproteinase-9 (MMP-9) protein level and enzyme activity. Western blot and ELISA showed that RUNX3 restoration inhibited the expression and secretion of vascular endothelial growth factor (VEGF). Taken together, our studies indicate that decreased expression of RUNX3 in human RCC tissue is significantly correlated with RCC progression. Restoration of RUNX3 expression significantly inhibits RCC cells migration, invasion and angiogenesis. These findings provide new insights into the significance of RUNX3 in migration, invasion and angiogenesis of RCC.
Insights
RUNX3 (runt-related transcription factor-3) is often decreased in renal cell carcinoma (RCC). Restoring RUNX3 inhibits RCC cell migration, invasion, and angiogenesis, suggesting its potential as a therapeutic target for kidney cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- RUNX3 (runt-related transcription factor-3) is a known tumor suppressor with antitumor activity.
- The role of RUNX3 in human renal cell carcinoma (RCC) remains largely unexplored.
Purpose of the Study:
- To investigate the clinical significance of RUNX3 expression in RCC patients.
- To elucidate the functional role of RUNX3 in RCC cell migration, invasion, and angiogenesis.
Main Methods:
- Immunohistochemistry on 75 RCC tissues and paired non-cancerous tissues using tissue microarray (TMA).
- Assays for cell migration, invasion, proliferation, and endothelial tube formation.
- Gelatin zymography, Western blot, ELISA to assess MMP-9 and VEGF levels.
Main Results:
- RUNX3 expression was significantly decreased in RCC tissues and correlated with tumor size, invasion depth, and TNM stage.
- Restoration of RUNX3 suppressed RCC cell migration and invasion.
- Overexpression of RUNX3 inhibited endothelial cell proliferation, tube formation, MMP-9 activity, and VEGF expression/secretion.
Conclusions:
- Decreased RUNX3 expression is linked to RCC progression.
- RUNX3 restoration inhibits RCC cell migration, invasion, and angiogenesis, highlighting its potential therapeutic role in kidney cancer.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Regulation of Angiogenesis and Blood Supply
